Adipose Stem Cells Modulate Immune Response in Sepsis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for systemic inflammatory response syndrome (SIRS), sepsis, and septic shock have shown limited efficacy, with high mortality rates and the need for new treatments due to the complex and overwhelming inflammatory responses these conditions induce.
Innovation Solution
Administration of human adipose tissue-derived stromal stem cells (hASCs) to regulate inflammatory cytokines, reduce leukocyte infiltration, and modulate the immune response, thereby providing a potential treatment for SIRS, sepsis, and septic shock.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapeutic strategies targeting pro-inflammatory mediators are used, then treatment is administered, but mortality rates remain high (30-50% for sepsis, 50-60% for septic shock)
Solution Approach 1:
The patent introduces mesenchymal stem cells (MSCs) as intermediary cells that mediate between the harmful inflammatory response and the host. These MSCs are administered to patients and function as biological modulators that regulate cytokine production, reduce leukocyte infiltration, and restore immune balance, thereby reducing mortality without directly targeting specific pro-inflammatory mediators
Solution Approach 2:
The patent employs the host's own stem cells (autologous MSCs) that are harvested, expanded, and returned to the patient. These self-derived cells carry the host's genetic information and immune profile, enabling them to integrate seamlessly into the host's biological system and provide tailored immunomodulation without requiring external cellular sources
2Reliability
If single cytokine blocking therapies are used, then specific inflammatory pathways are targeted, but efficacy is limited due to early and transient kinetic of inflammatory cytokines
Solution Approach 1:
The patent employs MSCs that perform multiple functions simultaneously: they modulate multiple cytokine pathways (TNF-α, IL-1β, IL-6, IL-10), regulate leukocyte infiltration across different tissues, and provide broad immunomodulation. This multi-functional approach is more effective than single-cytokine blocking and simplifies the overall therapeutic strategy by using one cell type to address multiple aspects of sepsis pathophysiology
Solution Approach 2:
The patent involves pre-harvesting and pre-expanding MSCs from the patient before the sepsis event. These cells are prepared in advance and stored, allowing for immediate administration when sepsis occurs. This preliminary preparation ensures that therapeutic cells are available at the critical time when they are most needed, overcoming the limitation of transient cytokine kinetics
Data Source
Figure 1
Figure 2A~2C
Figure 3A
AI summary
The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS.